SCHEMBL18006241

SCHEMBL18006241

Cc1noc(-c2ccccc2COc2cc(-c3nn[nH]c3C#N)cc(C(F)(F)F)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GABRA1 P14867 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
PDK2 Q15119 2/20 0.33
MCL1 Q07820 1/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18004114 0.85 KMT2A (0.40) KMT2ASMN1; SMN2BRD4PPARGPPARA
SCHEMBL18006236 0.82 L3MBTL1 (0.45) KMT2AMEN1POLBCYP1A2CYP2C9
SCHEMBL26070855 0.81 LMNA (0.30) LMNATHRB
SCHEMBL18004407 0.81 MAOB (0.39) BRD4
SCHEMBL18004444 0.81 GRIN1 (0.37) SMN1; SMN2GABRA1GABRG2GABRB3GABRA5
SCHEMBL18006186 0.80 CNR2 (0.37) KMT2AMEN1POLBSMN1; SMN2NPSR1
SCHEMBL16400186 0.80 CD274 (0.36) BRD4
SCHEMBL18006208 0.80 MCL1 (0.33) MCL1LMNABRD4PPARAPPARD
SCHEMBL18004323 0.80 ALOX5AP (0.42)
SCHEMBL18004441 0.79 RXRA (0.31) POLBPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KMT2A 865/4885MEN1 3151/4885POLB 539/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 KMT2A 865/4885MEN1 3151/4885POLB 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.